Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc.

District Court, M.D. Florida·Decided December 23, 2021·No. 8:21-cv-00942·Unknown

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

SHANDONG LUXI PHARMACEUTICAL CO., LTD.,

Plaintiff,

v. Case No: 8:21-cv-942-CEH-AEP

CAMPHOR TECHNOLOGIES, INC.,

Defendant. ___________________________________/ ORDER This matter comes before the Court on Defendant’s Motion to Compel Arbitration (Doc. 17). In the motion, Defendant Camphor Technologies, Inc. requests an order compelling the parties to arbitrate their disputes pursuant to the arbitration provision contained in the parties’ Exclusive Agency and Supply Agreements. Plaintiff filed a response in opposition (Doc. 30) and Defendant replied (Doc. 51). The Court, having considered the motion, responses, and being fully advised on the premises, will deny Defendant’s Motion to Compel Arbitration. BACKGROUND A. Factual Background Plaintiff Shandong Luxi Pharmaceutical Co., Ltd., (“Plaintiff”) is a manufacturer and developer of chemical compounds, and Defendant Camphor Technologies, Inc. (“Defendant”) is in the business of process development and commercial production of consumer pharmaceutical products. Doc. 37 ¶¶ 3–4. Since 2014, Plaintiff and Defendant have maintained a commercial business relationship with Defendant purchasing pharmaceutical products from Plaintiff. Id. ¶ 5. According to Plaintiff, the parties operated under agreements for sale and purchase from 2014–

2019, but their 2016 contract terminated at the end of 2019. Id. ¶¶ 6–8. Plaintiff claims that on January 28, 2020, the parties met and negotiated the resumption of their business relationship; but rather than being bound by a formal agreement, the parties agreed to be governed by each individual purchase order containing the terms and conditions of the sale. Id. ¶ 39. By contrast, Defendant claims the parties’ commercial

relationship has always been governed by a fully executed Exclusive Agency and Supply Agreement contract, with the most recent agreement executed in 2019 and effective through February 25, 2024. Doc. 17 ¶ 2. Plaintiff filed its Amended Complaint on May 21, 2021, which details the

underlying dispute whereby Plaintiff claims it fulfilled a Purchase Order submitted by Defendant, and Defendant took possession of the product but has refused to remit payment. Doc. 37 ¶¶ 45–52. Plaintiff further alleges that Defendant has threatened to employ assistance from United States agencies such as the Food and Drug Administration (“FDA”) and Customs and Border Protection (“CBP”) to seize future

shipments that Plaintiff lawfully imports into the United States intended for its other business partners. Id. ¶¶ 54–55. Plaintiff seeks injunctive relief enjoining Defendant or its agents from: (1) interfering with any future shipments of Plaintiff’s products lawfully imported and intended for other customers, and (2) transferring, encumbering, converting, or otherwise disposing of any of Plaintiff’s goods that are already in Defendant’s possession but have not been paid for. Id. ¶¶ 59. Plaintiff seeks additional relief under claims for breach of contract, conversion, tortious interference with a business relationship, unjust enrichment, and replevin. Id. ¶¶ 68, 75, 83, 90, 95,

101. The Court has jurisdiction pursuant to diversity of citizenship. Id. ¶ 13. On April 30, 2021, Defendant filed a Motion to Compel Arbitration, declaring that Plaintiff’s claims are subject to the parties’ long-standing agreement to arbitrate all disputes, which would still be applicable per the 2019 Agreement that Defendant

asserts is in full effect. Doc. 17 ¶¶ 2–3. In support of its motion, Defendant filed the affidavit of its president, Michael Creaturo. Doc. 18. In its motion to compel, Defendant contends the substantially same provision to arbitrate was included in each of the parties’ agreements executed in 2014, 2016, and 2019. Doc. 17 ¶ 2. The agreement to arbitrate excludes a party’s claim for

immediate injunctive relief and other provisional remedies that arise under the parties’ agreements. Id. ¶ 3. However, Defendant argues that Plaintiff’s attempt to seek an injunction in this case concerns matters which Plaintiff concedes are outside the purview of the parties’ agreement. Id. ¶ 3. Thus, Defendant contends that each of Plaintiff’s claims, including the request for injunction, is subject to arbitration. Id.

Plaintiff filed the affidavit of its counsel, Katherine Burghardt Kramer, in opposition. Doc. 30-1. In response to the motion to compel, Plaintiff argues that even if one of the contracts governs their relationship, the arbitration provision is unenforceable because the arbitration forum and procedural rules specified in the provision are unavailable. Doc. 30 at 1–2. Plaintiff contends that the forum and procedural rule selections were integral to the parties’ agreements to arbitrate; and where such is the case, an arbitration clause is null if the designated forum does not exist at the time an arbitrable dispute arises. Id. Arguing in the alternative, Plaintiff

alleges Defendant has waived any right to seek redress through arbitration because its conduct has been inconsistent with its position that the claims here are subject to arbitration. Id. Defendant denies that the forum or procedural rules are integral to the parties’ agreement and claims the Court may appoint a substitute arbitral forum where the

forum is unavailable. Doc. 51 at 2-3. In addition, Defendant contends that the 2019 Contract contained a severability clause, which allows a court to sever any invalid clause of the agreement and, in this instance, compel arbitration according to the remaining, valid terms of the parties’ agreement. Id.

B. Arbitration Agreement Defendant argues that the arbitration provision included in the 2014, 2016, and 2019 agreements are in substantially the same form, and it provides copies of the 2014 and 2019 arbitration provisions. Doc. 17 at 12–13; Doc. 17-1; Doc. 17-2. Plaintiff admits to the execution of the 2104 and 2016 Agreements, including the arbitration

clauses, but claims the 2016 Agreement expired at the end of 2019. Doc. 37 ¶ 8. Plaintiff provides a copy of the 2016 Agreement, which includes the following arbitration provision: 12. Governing Law and Venue: This Agreement shall be governed by and construed in accordance with the laws of the State of Florida U.S. District Court Middle District Florida without giving effect to the conflicts of law principles thereof. Any dispute arising out of this Agreement that is not amicably settled, except for seeking injunctive relief as provided below, shall be submitted to be resolved through final and binding arbitration by the Arbitration Institute of the United States Chamber of Commerce in accordance with its Arbitration Rules (the “Rules”). Any such arbitration will take place in Sarasota, Florida, USA. The number of arbitrators shall be one, and the arbitrator shall be selected by agreement of the Parties or, failing such agreement, shall be selected according to the relevant Rules. The Party against whom an award is passed shall bear the costs of such arbitrator. If either Party seeks judicial enforcement or review of such award, judgment may be entered upon such award in any court of competent jurisdiction.

The Arbitration clause shall not prevent either Party from bringing any claimed breach hereof before the ordinary courts for the purpose of applying for provisional remedies. Luxi submits to the jurisdiction of the courts of the State of Florida and the federal district court of the District of Florida for purposes of enforcement and interpretation of this agreement.

Free access — add to your briefcase to read the full text and ask questions with AI

Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc., (M.D. Fla. 2021).

Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc. (Shandong Luxi Pharmaceutical Co., Ltd. v. Camphor Technologies, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Solymar Investments, Ltd. v. Banco Santander S.A.
672 F.3d 981 (Eleventh Circuit, 2012)
Gibson v. Courtois
539 So. 2d 459 (Supreme Court of Florida, 1989)
St. Joe Corp. v. McIver
875 So. 2d 375 (Supreme Court of Florida, 2004)
Abraham Inetianbor v. Cashcall, Inc.
768 F.3d 1346 (Eleventh Circuit, 2014)
Christina Bazemore v. Jefferson Capital Systems, LLC
827 F.3d 1325 (Eleventh Circuit, 2016)
Ryan D. Burch v. P.J. Cheese, Inc.
861 F.3d 1338 (Eleventh Circuit, 2017)
Flagg v. First Premier Bank
644 F. App'x 893 (Eleventh Circuit, 2016)